STSs express multiple target genes relevant for ADC treatment and expression varies between and within the pathological types. This comprehensive ADC target landscape, based on the largest molecular epidemiology study in STS, should help clinicians and drug developers for further evaluation of ADCs across STS types.

2 months ago

Journal • PARP Biomarker • IO biomarker

PTK7 (Protein Tyrosine Kinase 7)

2ms

A Study of LY4175408 in Participants With Advanced Cancer (clinicaltrials.gov)

P1, N=240, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting

2 months ago

Enrollment open • First-in-human

3ms

PRO1107 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=33, Terminated, Genmab | Trial completion date: Jun 2028 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2028 --> Aug 2025; Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation

3 months ago

Trial completion date • Trial termination • Trial primary completion date

4ms

PRO1107 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=42, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=280 --> 42

4 months ago

Enrollment closed • Enrollment change

5ms

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov)

P1, N=65, Active, not recruiting, AbbVie | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

5 months ago

Trial completion date • Trial primary completion date

PTK7 (Protein Tyrosine Kinase 7)

cofetuzumab pelidotin (ABBV-647)

5ms

CAR19-T/NK cell and circular aptamer-drug conjugate (ApDC) combination treatment increases immunotherapy efficacy. (PubMed, Mol Cell Biochem)

A combination therapy composed of C-ApDC nanobodies and CAR19-T/NK cells was successfully developed. This innovative approach effectively enhances the cytotoxicity of CAR19-T/NK cells against tumour cells, providing a novel therapeutic strategy for tumour treatment and offering a promising solution to overcome CAR-T resistance.

5 months ago

Journal

PTK7 (Protein Tyrosine Kinase 7)

5ms

A Study of LY4175408 in Participants With Advanced Cancer (clinicaltrials.gov)

P1, N=240, Not yet recruiting, Eli Lilly and Company

5 months ago

New P1 trial

6ms

A Study of SKB518 in Patients With Lung Cancer (clinicaltrials.gov)

P2, N=80, Not yet recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

6 months ago

New P2 trial

6ms

Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. (PubMed, Mol Cancer Ther)

This study provides the first investigation of a PTK7-targeting antibody (OI-1) as an antibody-radionuclide conjugate (212Pb-labeled) in a preclinical model of intraperitoneal ovarian cancer. These results support further investigation of OI-1 as a candidate for targeted radionuclide therapy in PTK7-expressing cancers.

6 months ago

Preclinical • Journal

PTK7 (Protein Tyrosine Kinase 7)

7ms

PRO1107 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=280, Recruiting, Genmab | N=214 --> 280 | Trial completion date: Feb 2027 --> Jun 2028 | Trial primary completion date: Feb 2027 --> Jun 2028

7 months ago

Enrollment change • Trial completion date • Trial primary completion date